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Therapeutic Advances in Drug Safety
Introduction
Directive 2010/84/EC [The European Parliament 
and the Council of the European, 2010a] and 
Regulation [European Commission (EC)] No. 
1235/2010 [The European Parliament and the 
Council of the European, 2010b] overhauled the 
European Union’s (EU) pharmacovigilance 
framework established by Directive 2001/83/EC 
[The European Parliament and the Council of 
the European, 2001] on the community code 
relating to medicinal products for human use 
(hereinafter referred to as the Directive) and 
Regulation (EC) No. 726/2004 [The European 
Parliament and the Council of the European, 
2004] laying down community procedures for the 
authorization and supervision of medicinal prod-
ucts for human and veterinary use and establish-
ing a European Medicines Agency (EMA) 
(hereinafter referred to as the Regulation) [Borg 
et  al. 2011]. The amendments to the Directive 
and the Regulation became effective from July 
2012 and impacted the authorization require-
ments for a marketing authorization (MA) 
[introduction of a pharmacovigilance system 
master file (PSMF) instead of a detailed descrip-
tion of the pharmacovigilance system, as well as a 
risk management plan (RMP) becoming a 
requirement for all new products; postauthoriza-
tion measures were also enhanced with postau-
thorization safety studies (PASS) and 
postauthorization efficacy studies also becoming 
legally binding]. Furthermore, the EMA [for cen-
trally authorized products (CAPs)] and national 
competent authorities (NCAs) [for nationally 
authorized products (NAPs)] need to evaluate 
the effectiveness of risk minimization measures 
(RMMs) through scrutiny of company reporting 
on its RMMs and measurement of drug utiliza-
tion studies and health outcomes for key benefit–
risk issues. The new EU legislation also introduced 
clarity in the oversight by the authorities of non-
interventional studies: one member state is 
responsible for national oversight, while when 
more than one member state is involved then the 
EMA and its Pharmacovigilance and Risk 
Assessment Committee (PRAC) has the oversight 
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of both protocol agreement and results assess-
ment. In addition the new legislation provided for 
the development of an EU database listing all 
medicinal products authorized in the EU. This 
database will be populated by MA holders 
(MAHs) and lists for products subject to ‘addi-
tional monitoring’ which are labelled as such in 
the package leaflet will be compiled. With respect 
to adverse drug reaction (ADR) reporting, the 
ADR definition has been simplified to capture all 
noxious and unintended effects [including medi-
cation errors (MEs) resulting in harm] for report-
ing purposes. A shift in the definition has been 
made to allow the collection of information from 
all possible and available sources that will conse-
quently lead to the development of an increased 
pool of information, from which relevant signals 
and useful information can be extracted and ana-
lysed. While patients and healthcare professionals 
continue to report exclusively at national level, 
patient reporting of ADRs is now a right of citi-
zens in all EU member states. For the pharma-
ceutical companies, reporting suspected ADRs 
has been directed to EudraVigilance (the EU 
database of suspected ADRs) rather than to 
NCAs and thus creating a European pool of safety 
information. The EMA has been mandated to 
monitor literature (the EMA will monitor a 
selected list of substances and only in the scien-
tific databases, while Marketing Authorisation 
Holders (MAHs) have to screen substances not 
on the list and screen local publications) for indi-
vidual case reports of suspected ADR issues and 
to enter these into EudraVigilance and make 
them available to the pharmaceutical companies. 
The European Medicines Agency (EMA) is also 
mandated to report all European Union Adverse 
Drug Reactions (EU ADRs) regularly to the 
Uppsala Monitoring Centre of the World Health 
Organization. With respect to signal detection, 
this activity is now legally mandated and carried 
out for all products, where the EMA leads for 
Centrally Authorised Products (CAPs) and 
NCAs lead for NAPs with support from the 
EMA. Changes to periodic safety update reports 
(PSURs) according to International Conference 
on Harmonisation (ICH) E2C(R2) and good 
pharmacovigilance practice (GVP) Module VIII 
have also been introduced where these have 
become an evaluation of the benefits and risks of 
the product and are based on all cumulative data 
(rather than interval data as before). A periodic 
benefit–risk evaluation report is being generated 
with a view to examining the benefit–risk ratio 
throughout the lifecycle of the medicinal product. 
Within the EMA, a new committee PRAC has 
been established focusing on Periodic Safety 
Update Reports (PSURs), referrals, Post 
Authorisation Safety Study (PASS), risk manage-
ment, signal detection and evaluation and effec-
tiveness of Risk Minimisation Measures(RMMs). 
PRAC can be viewed as the major advisory board 
on aspects of safety for Committee for Human 
Medicinal Products (CHMP), a European 
Medicines Agency, when it relates to centrally 
authorized products or applications submitted 
through the centralized procedure and for 
National Competent Authorities(NCAs) through 
their coordination group; Pharmacovigilance and 
Risk Assessment Committee (PRAC) recommen-
dations are sent to CHMP or the coordination 
group for adoption as appropriate.
At preauthorization stage, safety assessment 
focuses on the totality of the data collected up to 
the point of the application for MA and it can be 
considered as an exhaustive assessment. The 
amendments in the legislation shifted part of the 
assessment burden from the preauthorization 
stage and placed emphasis on the surveillance in 
the postauthorization setting. Several medicinal 
products have been withdrawn due to safety issues 
over the past 15 years and these are summarized 
in Table 1. These can be considered the main 
drivers for the change in the regulatory approach 
and the enhancement of the pharmacovigilance 
procedures and activities. Other reasons for the 
change in the legislation included the realization 
that all the information for the safety of a medici-
nal product cannot be known at the time of 
authorization; limitations and uncertainties in the 
data submitted and acceptable lack of knowledge 
at the time of authorization that cannot be com-
pleted unless the product enters the markets; 
diversity in the population of patients who will 
use the medicinal product that cannot be foreseen 
at the time of authorization. Finally the need to 
increase the pool of information including all 
available sources such as patients and literature 
reports is also an important driver of the change 
in the legislation.
It is easily understandable that the legislative 
change meant a significant increase in workload 
within pharmacovigilance departments across all 
sectors, with some postulating that the industry 
expected a 2030% increase alone in case volume 
[Borg et  al. 2011; Garattini and Bertele, 2011; 
Tanti et  al. 2013]. In this review, we examined 
the implementation of the pharmacovigilance 
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Table 1. Examples of drugs withdrawn for safety reasons in all European Union member states between 2000 and 2011 (modified 
from McNaughton et al. [2014] and Post-Licensing Directorate [2011]).
Drug name Drug class or use Year of withdrawal Adverse reaction or safety concern
Cisapride Increase motility in the 
gastointestinal tract
2000 Risk of cardiac arrhythmias
Phenypropolamine Nasal congestion, control of 
urinary incontinence, priapism 
and obesity
2000 Risk of stroke in women under 50 years 
of age when taken at high doses for 
weight loss
Trovafloxacin Antibiotic 2001 Risk of unpredictable liver injury
Cerivastatin Antilipidaemic agent 2001 Risk of rhabdomyolysis
Nefazodone Antidepressant 2003 Hepatotoxicity
Rofecoxib NSAID (COX-2 inhibitor) 2004 Thrombotic events
Coproxamol 
(dextropropoxyphene)
Analgesic 2004 Withdrawn in UK due to overdosage 
dangers
Thioridazine Neuroleptic (α-adrenergic 
and dopaminergic receptor 
antagonist)
2005 Cardiac disorders
Valdecoxib NSAID (COX-2 inhibitor) 2005 Cardiovascular and cutaneous 
disorders
Ximelagatran/
melagatran
Anticoagulant (thrombin 
inhibitor)
2006 Hepatotoxicity
Carisoprodol Muscle relaxant 2007 Intoxication, psychomotor impairment, 
addiction, misuse
Clobutinol Cough suppressant (centrally 
acting)
2007 QT prolongation
Veralipride Neuroleptic (and dopaminergic 
receptor antagonist)
2007 Neurological and psychiatric disorders
Lumiracoxib NSAID (COX-2 inhibitor) 2007 Hepatotoxicity
Inhaled insulin Antidiabetic treatment 2007 Withdrawn voluntarily following 
restrictions on prescribing, doubts over 
long-term safety
Rimonabant Treatment of obesity 
(cannabinoid receptor 
antagonist)
2008 Psychiatric disorders
Benfluorex (nonspecific β agonist) Anorectic 
and hypolipidaemic
2009 Heart valve disease, pulmonary 
hypertension
Dextropropoxyphene Opioid painkiller 2009 Fatal overdose
Efalizumab For treatment of moderate to 
severe chronic plaque psoriasis
2009 Increased risk of progressive multifocal 
leukoencephalopathy
Orciprenaline Sympathomimetic 2010 Cardiac disorders
Sibutramine Treatment of obesity (serotonin 
noradrenaline reuptake 
inhibitor)
2010 Cardiovascular disorders
Rosiglitazone Antidiabetic treatment (PPAR 
agonist)
2010 Cardiovascular disorders
Sitaxentan Antihypertensive (endothelin 
receptor antagonist)
2010 Hepatotoxicity
Bufexamac NSAID 2010 Contact allergic reactions
Buflomedil Vasodilator (α1 and α2 receptor 
antagonist)
2011 Neurological and cardiac disorders 
(sometimes fatal)
Aceprometazine + 
acepromazine + 
clorazepate
Hypnotic 2011 Cumulative adverse effects, misuse, 
fatal side effect
COX, cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug; Peroxisome Proliferator-Activated Receptor, PPAR.
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legislative framework by EU regulators with the 
aim of mapping out whether the Directive and 
Regulation are strengthening and rationalizing 
pharmacovigilance in the EU.
Literature search methodology
To identify relevant literature, we performed an 
EU Council Public Register, EU Parliament 
Public Register, EU Committee of Regions 
Public Register, EUROPA (EC), Eur-Lex, and 
European Medicines Agency search (December 
2010–September 2014). We used the search term 
'pharmacovigilance' and included all documents 
written in English.
Results and discussion
Legislative updates
In 2012, the EC adopted legislative proposals (a 
Directive and a Regulation) to amend once again 
the European legislation on pharmacovigilance 
[The European Parliament and the Council of 
the European, 2012a, 2012b]. This followed the 
issue with the ‘mediator case’ in France. Mediator 
was a medicinal product prescribed to patients 
with diabetes and obesity. A number of deaths 
associated with the use of this product from car-
diovascular events were observed by health pro-
fessionals and not through the usual 
pharmacovigilance means. The case of ‘mediator’ 
has had consequences in the way pharmacovigi-
lance is conducted in one member state and in 
Europe as a network through changes to the leg-
islation. To avoid such scenarios being repeated, 
the EC ‘stressed’ (tested) the recently amended 
EU’s pharmacovigilance regulations (Directive 
2010/84/EU) with respect to situations that could 
potentially mimic the ‘mediator’ scenario. There 
is also the well known story of thalidomide that 
was used for morning sickness in pregnant women 
and its administration led to severe malformation 
of the limbs in the infants born to these women. 
The case of thalidomide was the main reason for 
the strengthening of the legislation and establish-
ing the regulation of medicines globally in the 
1960s. It is considered as the first case that intro-
duced strict regulations and initiated rigorous 
assessment of all safety information available. 
Another known case that received a lot of public-
ity and criticism internationally is the case of 
rofecoxib, a cyclooxygenase-2 inhibitor (coxib), 
which is a nonsteroidal anti-inflammatory drug 
removed from the market due to safety concerns 
(increased risk of serious heart disease, heart 
attack and stroke associated with long-term, high-
dosage use).
On the basis of this and other previous safety with-
drawals in pharmaceutical history (please see 
Table 1), gaps in the legislation across all regions 
of the world were identified. Specifically, EU legis-
lation issues were identified and addressed through 
Directive 2012/26/EC whereby harmonized 
EU-wide triggered arbitration procedures have 
become automatic for the most important issues. 
As a consequence, member states do not act uni-
laterally when it comes to issues of drug safety 
[The European Parliament and the Council of 
the European, 2012a, 2012b]. The Directive has 
been applicable to all member states from 28 
October 2013. In 2012, the EC published an 
Implementing Regulation (referred to as the CIR), 
setting the minimum requirements for the quality 
systems of both MAHs and NCAs for the perfor-
mance of pharmacovigilance activities [European 
Commission, 2012]. This CIR is the standard to 
which pharmacovigilance audits on pharmacovig-
ilance systems are implemented and thus consid-
ered by the authors as of critical importance for all 
actors in the sector. Under the new legislation, 
uncertainties in safety as in the case of coxibs can 
now be handled proactively by a detailed RMP 
capable of identifying potential risks, efficient 
RMMs and by allowing additional postauthoriza-
tion safety studies, while triggering a referral pro-
cedure and as a consequence a thorough review of 
all available data is also considered as a suitable 
option. Interestingly, only one withdrawal of a 
marketed product has been observed up to April 
2015 since the implementation of the new legisla-
tion in 2012.
The primary concern identified by the Fraunhofer 
report in 2006 [Biihrlen et al. 2006] that EU reg-
ulators were acting in disharmony when taking 
regulatory action on safety issues across all 
medicinal products irrespective of the approval 
procedure (CAPs or NAPs) is considered to be 
resolved.
In 2014, the EC adopted a Regulation 658/2014/
EC to introduce fees for pharmacovigilance activ-
ities at the level of the EMA. Fees have been 
introduced for referrals, PSURs and imposed 
noninterventional safety study protocol evalua-
tions. These fees will be used largely to compen-
sate the rapporteur teams in the NCAs of the 
member states who will perform the assessments 
Therapeutic Advances in Drug Safety 6(4)
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for the PRAC. In addition, an annual fee payable 
to the EMA for national authorized products for 
information technology systems and databases, 
and signal detection activities has also been intro-
duced. Annual fees to cover these mentioned 
activities of the EMA apply from January 2015. 
The EMA will start charging from 1 July 2015 
[The European Parliament and the Council of 
the European, 2014].
The PRAC
The PRAC was set up in July 2012 and meets 
every month at the EMA. Analysing the monthly 
agendas of the PRAC on the EMA website (www.
ema.europa.eu), it is interesting to note that since 
September 2012, the items for discussion grew 
steadily from 17 product-related issues and not 
procedural aspects (September 2012), to around 
103 (January 2013), peaking at 222 (September 
2014) and settling at around 138 (January 2014 to 
December 2014). Interestingly, the following fre-
quency sequence of PRAC agenda item topics 
have been recorded: RMP (36.7–42.3%), PSURs 
(26.6–34.6%), signal detection (7.4–14%), 
CHMP safety issues (5.3%), PASS (3.4–17.6%), 
Article 31 referrals (i.e. risk–benefit referrals; 
3.3%), pharmacovigilance inspections (2.2%), 
Coordination Group for Mutual Recognition and 
Decentralised Procedures (human) (CMDh) 
safety issues (1.4%), Article 107 referrals (i.e. 
urgent safety procedures; 1.3%), Article 5(3) 
referrals (executive director or member state refer-
rals on issues of interest; 0.16%). From July 2012 
to March 2015, there have been 8 Article 107i 
referrals, 8 Article 20 referrals and 23 Article 31 
referrals. The results indicate that the PRAC work-
load is considerable and that the member states 
(through assessors) and the EMA (through scien-
tific administrators) have responded to the man-
date directed by the EU pharmacovigilance 
legislation. Table 2 is indicative of the PRAC activ-
ities, with examples of substances and medicinal 
products, and the outcome.
Good vigilance practices
A key deliverable of the Directive is development 
and implementation of a guideline on GVP. These 
practices constitute a set of measures with the 
scope of regulating the performance of pharma-
covigilance in the EU. This guideline is applicable 
for MAHs and EU regulators (for all medicinal 
products: NAPs and CAPs) and is divided into 
chapters that fall into two categories: modules 
covering major pharmacovigilance processes; and 
product- or population-specific considerations 
(the latter are still under development). GVP 
Modules I–XVI cover major pharmacovigilance 
processes and are available on the EMA website 
(www.ema.europa.eu). Effectively, the GVP mod-
ules replace Volume 9A of The Rules Governing 
Medicinal Products in the European Union – 
Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use [European Commission 
2008]. For convenience, we have summarized the 
key elements that the GVP modules deal with in 
Table 3.
Periodic safety update reports
The recently published CIR (EU) No. 520/2012 
[European Commission, 2012] has set the for-
mat and structure of PSURs, while more infor-
mation on details and guidance for the submission 
of PSURs in the EU, data lock points and the 
frequency of submission are provided in GVP 
Module VII ‘Periodic safety update report’ (www.
ema.europa.eu). The International Conference 
on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
has developed an ICH harmonized tripartite 
guideline for the periodic benefit–risk evaluation 
report E2C(R2) that provides guidance on how 
periodic benefit–risk evaluation reporting on 
marketed products among the ICH regions 
should be formatted by MAHs for the evaluators 
and agencies. Importantly, the structure of 
PSURs has changed to an integrated benefit–risk 
analysis for authorized indications of the active 
substance covered in the PSUR. Thus it is 
expected that MAHs characterize both the risks 
and benefits and then critically appraise the 
uncertainties thereof. MAHs can now submit 
PSURs electronically to the EMA only as mem-
ber states will have access to these submissions 
through a repository (available in 2015). Single 
assessments are carried out by drug substance in 
a procedure where all MAHs for products con-
taining a particular substance submit PSURs at 
the same time for assessment at the PRAC 
(although PSURs for generic products are not 
routinely submitted). The PSURs assessed by the 
PRAC will cover any mix of CAPs and NAPs 
(including through the mutual recognition and 
decentralized procedures). The continuous circle 
of collecting data, reporting and evaluating them 
reassures us that the dynamics post approval have 
not changed and the benefit–risk ratio which was 
used to grant the MA is still favourable. It is 
JJ Borg, A Tanti et al.
http://taw.sagepub.com 125
Table 2. Examples of Pharmacovigilance Risk Assessment Committee (PRAC) activities for certain active substances between 
September 2014 and February 2015 (6-month period).
Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Ivabradine
 
6 February 
2015
C01EB
Cardiovascular system, other 
cardiac preparations
Article 20 Assessment report – PI, SmPC 
and PL amendments, variation 
to the MA terms, updated RMP 
and DHPCs of Corlentor and 
Procoralan 
Ambroxol
 
12 January 
2015
R05CB06
Respiratory system, expectorants, 
excl. combinations with cough 
suppressants
Article 31 
referral
PRAC recommendations – 
update of PI (risk of allergic 
reactions)
 
Bromhexine
 
12 January 
2015
R05CB02
Respiratory system, expectorants, 
excl. combinations with cough 
suppressants
Article 31 
referral
PRAC recommendations – 
update of PI (risk of allergic 
reactions)
 
Vildagliptin
 
22 December 
2014
A10BH02
Alimentary tract and metabolism, 
drugs used in diabetes,blood 
glucose lowering drugs, excl. 
insulins
Signal 
assessment
PRAC recommendations on 
signals – update of SmPC and 
PIL (myalgia, renal failure, 
interstitial lung disease) 
Interferons
 
22 December 
2014
L03AB
Antineoplastic and 
immunomodulating 
agents, immunostimulants, 
immunostimulants
Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(pulmonary arterial 
hypertension) 
Lenalidomide 22 December 
2014
L04AX04 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(Parkinson’s disease)
 
 Antineoplastic and 
immunomodulating agents, 
immunosuppressants, 
immunosuppressants
Natalizumab 22 December 
2014
L04AA23 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(anaemia) 
 Antineoplastic and 
immunomodulating agents, 
immunosuppressants, 
immunosuppressants
Trabectedin 22 December 
2014
L01CX01 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(capillary leak syndrome)
 
 Antineoplastic and 
immunomodulating agents, 
antineoplastic agents,plant 
alkaloids and other natural 
products
Dimethyl fumarate, 
(fumaric acid 
esters) 
25 November 
2014
N07XX09 Signal 
assessment
PRAC recommendations 
on signals – update of 
PI, DHPC, updated RMP 
(progressive multifocal 
leukoencephalopathy) 
Nervous system, other nervous 
system drugs, other nervous 
system drugs
Leuprorelin
 
25 November 
2014
L02AE02
Antineoplastic and 
immunomodulating 
agents,endocrine 
therapy,hormones and related 
agents
Signal 
assessment
PRAC recommendations 
on signals – update of PI, 
DHPC, updated RMP routine 
and additional PV and RMM 
(medication error, wrong 
technique in drug usage 
process) 
(Continued)
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Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Aripiprazole 25 November 
2014
N05AX12 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(aggression and related events) 
 Nervous system, psycholeptics, 
antipsychotics
Gadodiamide 25 November 
2014
V08CA03 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(nephrogenic systemic fibrosis 
in patients with acute kidney 
injury) 
 Various, contrast media, magnetic 
resonance imaging contrast media
Infliximab 25 November 
2014
L04AB02 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(rhabdomyolysis)
 
 Antineoplastic and 
immunomodulating agents, 
immunosuppressants, 
immunosuppressants, tumour 
necrosis factor α inhibitors
Methylprednisolone 25 November 
2014
H02AB04 Signal 
assessment
PRAC recommendations on 
signals – assessment in next 
PSUR (hepatotoxicity after high-
dose intravenous use)
 
 Systemic hormonal preparations, 
excl. sex hormones and insulins, 
corticosteroids for systemic use, 
corticosteroids for systemic use, 
plain glucocorticoids
Paliperidone 25 November 
2014
N05AX13 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics
Aripiprazole 25 November 
2014
N05AX12 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics
Lurasidone 25 November 
2014
N05AE05 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics, indole derivatives
Asenapine 25 November 
2014
N05AH05 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics, diazepines, 
oxazepines, thiazepines and 
oxepines
Clozapine 25 November 
2014
N05AH02 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure)
 
 Nervous system, psycholeptics, 
antipsychotics, diazepines, 
oxazepines, thiazepines and 
oxepines
Risperidone 25 November 
2014
N05AX08 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics
Sertindole
 
25 November 
2014
N05AE03
Nervous system, psycholeptics, 
antipsychotics, indole derivatives
Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
(Continued)
Table 2. (Continued)
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Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Quetiapine 25 November 
2014
N05AH04 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system psycholeptics, 
antipsychotics, diazepines, 
oxazepines, thiazepines and 
oxepines
Ziprasidone 25 November 
2014
N05AE04 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics, indole derivatives
Zotepine 25 November 
2014
N05AX11 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute renal failure) 
 Nervous system, psycholeptics, 
antipsychotics
Pantoprazole 25 November 
2014
A02BC02 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(subacute cutaneous lupus 
erythematosus) 
 Alimentary tract and metabolism, 
drugs for acid-related disorders, 
drugs for peptic ulcer and gastro-
oesophageal reflux disease, proton 
pump inhibitors
Radium-223 
dichloride 
25 November 
2014
V10XX03 Signal 
assessment
PRAC recommendations on 
signals – assessment in next 
PSUR (cerebral haemorrhage)
 
Various, therapeutic 
radiopharmaceuticals, other 
therapeutic radiopharmaceuticals, 
various therapeutic 
radiopharmaceuticals
Sorafenib 25 November 
2014
L01XE05 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(acute generalized 
exanthematous pustulosis) 
 Antineoplastic and 
immunomodulating agents, 
antineoplastic agents, other 
antineoplastic agents, protein 
kinase inhibitors
Vemurafenib 25 November 
2014
L01XE15 Signal 
assessment
PRAC recommendations on 
signals – assessment in next 
PSUR (Dupuytren’s contracture) 
 Antineoplastic and 
immunomodulating agents, 
antineoplastic agents, other 
antineoplastic agents, protein 
kinase inhibitors
Bisphosphonates 25 November 
2014
M05BA Signal 
assessment
PRAC recommendations 
on signals – routine 
pharmacovigilance (heart valves 
disorders) 
 Musculoskeletal system, drugs 
for treatment of bone diseases, 
dugs affecting bone structure and 
mineralization
Strontium ranelate 25 November 
2014
M05BX03 Signal 
assessment
PRAC recommendations 
on signals – routine 
pharmacovigilance (heart valves 
disorders)
 
 Musculoskeletal system, drugs 
for treatment of bone diseases, 
drugs affecting bone structure 
and mineralization, other drugs 
affecting bone structure and 
mineralization
Octocog α
 
25 November 
2014
B02BD02
Blood and blood forming organs 
antihaemorrhagics, vitamin K 
and other haemostatics, blood 
coagulation factors
Signal 
assessment
PRAC recommendations on 
signals – no action at this 
stage (inhibitor development in 
previously untreated patients) 
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Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Valproic acid 14 November 
2014
N03AG01 Article 31 
referral
Assessment report – PI 
amendment, other RMMs 
(pregnancy and women of 
childbearing potential) 
 Nervous system, antiepileptics, 
antiepileptics, fatty acid derivatives
Valproate 
semisodium 
14 November 
2014
N03AG01 Article 31 
referral
Assessment report – PI 
amendment, other RMMs 
(pregnancy and women of 
childbearing potential) 
Nervous system, antiepileptics, 
antiepileptics, fatty acid derivatives
Valpromide 14 November 
2014
N03AG02 Article 31 
referral
Assessment report – PI 
amendment, other RMMs 
(pregnancy and women of 
childbearing potential) 
 Nervous system, antiepileptics, 
antiepileptics, fatty acid derivatives
Ponatinib 10 November 
2014
L01XE24, Assessment report – PI 
amendment, variation to the 
MA terms, RMM and additional 
pharmacovigilance (vascular 
occlusive events) 
 antineoplastic and 
immunomodulating agents, 
antineoplastic agents, other 
antineoplastic agents, protein 
kinase inhibitors
Aflibercept 28 October 
2014
Not assigned Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(Higher systemic exposure 
compared with ranibizumab 
after intravitreal injection)
Amiodarone 28 October 
2014
C01BD01 Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(syndrome of inappropriate 
antidiuretic hormone 
secretion) 
 Cardiovascular system, cardiac 
therapy, antiarrhythmics, class I 
and III, antiarrhythmics, class III
Exenatide 28 October 
2014
A10BX04 Signal 
assessment
PRAC recommendations on 
signals – assessment in next 
PSUR (goitre and worsening/
enlargement of goitre)
 
 Alimentary tract and metabolism, 
drugs used in diabetes, blood 
glucose lowering drugs, excl. 
insulins, other blood glucose 
lowering drugs, excl. insulins
Tocilizumab 28 October 
2014
L04AC07 Signal 
assessment
PRAC recommendations on 
signals – assessment in next 
PSUR (cholecystitis)
 
 Antineoplastic and 
immunomodulating agents, 
immunosuppressants, 
immunosuppressants, interleukin 
inhibitors
Atazanavir 28 October 
2014
J05AE08 Signal 
assessment
PRAC recommendations 
on signals – routine 
pharmacovigilance (haemolytic 
anaemia)
 
 Anti-infectives for systemic 
use, antivirals for systemic use, 
direct acting antivirals, protease 
inhibitors
Sodium (sodium-
containing 
effervescent, 
dispersible and 
soluble medicines)
28 October 
2014
 Signal 
assessment
PRAC recommendations on 
signals – no action at this stage 
(cardiovascular events)
(Continued)
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Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Testosterone 5 December 
2014
G03BA03 Assessment report – 
amendments to PI, variation to 
the MA terms (cardiovascular 
events)
 
 Genitourinary system and sex 
hormones, sex hormones and 
modulators of the genital system, 
androgens, 3-oxoandrosten (4) 
derivatives
Abiraterone 30 September 
2014
L02BX03 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormone 
antagonists and related agents, 
other hormone antagonists and 
related agents
Degarelix 30 September 
2014
L02BX02 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormone 
antagonists and related agents, 
other hormone antagonists and 
related agents
Buserelin 30 September 
2014
L02AE01 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormones 
and related agents, gonadotropin 
releasing hormone analogues
Leuprorelin 30 September 
2014
L02AE02 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormones  
and related agents,  
gonadotropin releasing  
hormone analogues
Goserelin 30 September 
2014
L02AE03 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormones 
and related agents, gonadotropin 
releasing hormone analogues
Triptorelin 30 September 
2014
L02AE04 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormones 
and related agents, gonadotropin 
releasing hormone analogues
Histrelin
 
30 September 
2014
L02AE05
Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormones 
and related agents, gonadotropin 
releasing hormone analogues
Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
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Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Abarelix 30 September 
2014
L02BX01 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormone 
antagonists and related agents, 
other hormone antagonists and 
related agents
Flutamide 30 September 
2014
L02BB01 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormone 
antagonists and related agents, 
anti-androgens
Nilutamide 30 September 
2014
L02BB02 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormone 
antagonists and related agents, 
antiandrogens
Bicalutamide 30 September 
2014
L02BB03 Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
 
 Antineoplastic and 
immunomodulating agents, 
endocrine therapy, hormone 
antagonists and related agents, 
antiandrogens
Enzalutamide 30 September 
2014
Not assigned Signal 
assessment
PRAC recommendations on 
signals – update of PI (QT 
interval prolongation due to 
long-term use)
Chlorhexidine 
gluconate
 
30 September 
2014
B05CA02 Signal 
assessment
PRAC recommendations 
on signals – SmPC and PL 
amendments, strengthening 
of pharmacovigilance activities 
(chemical injury, burns when 
used in skin disinfection in 
premature infants) 
Blood and blood forming organs, 
blood substitutes and perfusion 
solutions, irrigating solutions, anti-
infectives
Imatinib 30 September 
2014
L01XE01 Signal 
assessment
PRAC recommendations 
on signals – SmPC and PL 
amendments, submission 
in next PSUR (decreased 
estimated glomerular filtration 
rate) 
 Antineoplastic and 
immunomodulating agents, 
antineoplastic agents, other 
antineoplastic agents, protein 
kinase inhibitors
Temozolomide 30 September 
2014
L01AX03 Signal 
assessment
PRAC recommendations on 
signals – assessment in next 
PSUR (dehydration leading to 
renal failure)
 
 Antineoplastic and 
immunomodulating agents, 
antineoplastic agents, alkylating 
agents, other alkylating agents
Thiotepa
 
30 September 
2014
L01AC01
Antineoplastic and 
immunomodulating agents, 
antineoplastic agents, alkylating 
agents, ethylene imines
Signal 
assessment
PRAC recommendations 
on signals – submission of 
supplementary information 
(pulmonary arterial 
hypertension) 
(Continued)
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Table 3. Good pharmacovigilance practice (GVP) modules.
GVP title Comments
Guideline on good pharmacovigilance 
practices: Module I – Pharmacovigilance 
systems and their quality systems
This Module provides guidance to MAHs, NCAs and EMA in order for them 
to establish and maintain pharmacovigilance systems that have been 
through quality assurance processes
 Pharmacovigilance system is defined in Article 1 of Directive 2001/83/EC 
as a system that should be used by the MAHs and by NCAs to perform the 
tasks and to assume the responsibilities included in Directive’s Title IX for 
Pharmacovigilance. The pharmacovigilance system should be designed to 
monitor the safety of already authorized medicinal products and should be 
able to detect any change to their favourable benefit/risk ratio
Guideline on good pharmacovigilance 
practices: Module II – Pharmacovigilance 
system master file
Module II contains guidance related to the requirements for the 
pharmacovigilance system master file, as well as procedures for its 
maintenance, adaptation of the content and inclusion of subsequent 
submissions to NCAs
Guideline on good pharmacovigilance 
practices: Module III – Pharmacovigilance 
inspections
Module III provides detailed guidance on the procedures how to plan, 
conduct, report and perform follow up of pharmacovigilance inspections 
in the EU. Module III also provides an outline of the roles of the different 
parties involved. While general guidance is included in section III.B, 
section III.C contains the overall operation procedures and processes of 
pharmacovigilance inspections in the EU
Guideline on good pharmacovigilance 
practices: Module IV – Pharmacovigilance 
audits
Module IV contains guidance on how to plan and conduct legally required 
audits (that can be called ‘internal inspections’). The aim of this module 
is the facilitation of the performance of pharmacovigilance audits and 
promotion of a harmonized approach, and encouragement of consistency 
and simplification of the audit processes. Internationally accepted auditing 
standards from international auditing standardization organizations have 
been used as the basis for the principles of this module
Active substance Date of issue ATC code of active substance Type of 
procedure
Outcome (type of publication; 
action taken; issue 
investigated)
Cefepime 30 September 
2014
J01DE01 Signal 
assessment
PRAC recommendations 
on signals – routine 
pharmacovigilance 
(convulsions) 
 Anti-infectives for systemic use, 
antibacterials for systemic use, 
other β-lactam antibacterials, 
fourth-generation cephalosporins
Diacerein 19 September 
2014
M01AX21 Article 31 
referral
Assessment report 
– amendments to PI 
(gastrointestinal risk and 
potential risk of hepatic 
reactions) 
 Musculoskeletal system, anti-
inflammatory and antirheumatic 
products, anti-inflammatory 
and antirheumatic products, 
nonsteroids, other anti-
inflammatory and antirheumatic 
agents, nonsteroids
Bromocriptine
 
2 September 
2014
G02CB01
Genitourinary system and sex 
hormones, other gynaecologicals, 
other gynaecologicals, prolactine 
inhibitors
Article 31 
referral
Assessment report – 
amendments to PI, variation to 
the MA terms (cardiovascular, 
neurological and psychiatric 
side effects) 
DHPC, Dear Healthcare Professional Communication; MA, marketing authorization; PI, Product Information; PIL product information leaflet; PL, patient 
leaflet; PSUR, periodic safety update report; RMM, risk minimization measure; RMP, risk management plan; SmPC, summary of product characteristics.
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GVP title Comments
Guideline on good pharmacovigilance 
practices: Module V – Risk management 
systems
Module V provides guidance on risk management systems for medicinal 
products for human use and replaces the relevant guidance in Volume 
9A. This Module is making a step further than managing risks. However, 
when considering how to evaluate the benefit/risk balance, risks have to 
be clarified and understood in the context of benefit and they should be 
evaluated against it. In assessing the benefit–risk balance at the time of 
authorization, it is assumed that these benefits and risks apply to the totality 
of the target population. However, there may be subgroups of patients with 
greater risk than that for the whole target population, patients for whom 
the benefit does not appear to extend as much as the mean for the whole 
target population. It is widely acknowledged that the clinical trial setting is 
a controlled environment and in that sense it may not represent the true 
effectiveness of the medicinal product in everyday medical practice and as 
a result the benefit/risk ratio assessment at the time of approval will most 
likely change post-approval
Guideline on good pharmacovigilance 
practices: Module VI – Management and 
reporting of adverse reactions to medicinal 
products
Module VI contains the legal requirements detailed in Title IX of Directive 
2001/83/EC [DIR] and chapter 3 of Regulation (EC) No 726/2004 [REG], 
which are applicable to NCAs, MAHs and the EMA in relation to the 
collection, data management and reporting of suspected adverse reactions 
(serious and nonserious), which are associated with medicinal products for 
human use authorized in the EU. Reporting of emerging safety issues or of 
suspected adverse reactions that occur in special situations are described 
in this Module and relevant recommendations are provided
Guideline on good pharmacovigilance 
practices (GVP): Module VII – Periodic safety 
update report
Module VII contains guidance relevant to the preparation, submission and 
assessment of PSURs. PSURs are pharmacovigilance documents intended 
to provide an evaluation of the benefit–risk balance of a medicinal product 
submitted by marketing authorization holders covering predefined time 
periods of the product’s lifecycle during the postauthorization phase
 The format of PSURs shall follow a specific structure which is described in 
the IR Article 35
Guideline on good pharmacovigilance 
practices: Module VIII – Postauthorization 
safety studies
Module VIII provides guidance for the postauthorization safety studies 
(PASS), which are clinical trials or noninterventional studies. Module VIII 
does not deal with nonclinical safety studies
 A PASS is defined in Directive 2001/83/EC (DIR) Art 1(15) and it is any study 
relating to an authorized medicinal product conducted with the aim of 
identifying, characterizing or quantifying a safety hazard, confirming the 
safety profile of the medicinal product, or evaluating the effectiveness of 
risk management measures
 A PASS may be initiated, managed or financed by a marketing authorization 
holder voluntarily, or can be imposed by a competent authority [DIR Art 
107m(1), Regulation (EC) No. 726/2004 (REG) Art 28b]
Guideline on good pharmacovigilance 
practices: Module VIII addendum I – Member 
states' requirements for transmission 
of information on noninterventional 
postauthorization safety studies
The tables included in the addendum specify member states’ requirements 
for the transmission of information on postauthorization safety studies 
initiated, managed or financed by MAHs voluntarily or pursuant to an 
obligation
Guideline on good pharmacovigilance 
practices: Module IX – Signal management
The Report of the Council for International Organizations of Medical Sciences 
Working Group VIII Practical Aspects of Signal Detection in Pharmacovigilance 
(CIOMS, Geneva 2010) defines a signal as ‘information that arises from one or 
multiple sources (including observations and experiments), which suggests 
a new potentially causal association, or a new aspect of a known association, 
between an intervention and an event or set of related events, either adverse 
or beneficial, that is judged to be of sufficient likelihood to justify verificatory 
action’
 Module IX is considering only new information related to adverse effects
(Continued)
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GVP title Comments
 In order to suggest a new potentially causal association or a new safety 
aspect of a known association, any signal should be validated taking into 
account other relevant sources of information
 The process used for signal management can be defined as the set of 
activities attempting to determine whether new risks associated with an 
active substance or a medicinal product exist or whether known risks have 
been modified. These activities are examining individual case safety reports, 
collected data from active surveillance systems or studies, literature reports 
and published information or other data sources. The signal management 
process shall include initial signal detection throughout their validation 
and confirmation, analysis and prioritization. Signal assessment to the 
recommendation of an action, as well as the tracking of the steps taken 
should also be included [IR Art 21(1)]
Guideline on good pharmacovigilance 
practices: Module X – Additional monitoring
The 2010 EU pharmacovigilance legislation, further amended in 2012, has 
introduced a different approach and the framework for the enhancement of 
data collection which is postauthorization risk proportionate for medicinal 
products. This can include additional monitoring for certain medicinal 
products with a view to strengthen the safety monitoring of these medicinal 
products
This Module is divided in two sections:
X.B. describes the general principles how to assign status of additional 
monitoring to medicinal products as well as how to communicate and deal 
with transparency aspects
X.C. provides the principles for the operation of the EU network regarding 
the activities to supervise additionally monitored medicinal products, 
and define the strategy for communication together with the impact on 
pharmacovigilance tasks and activities.
 
 
 
Guideline on good pharmacovigilance 
practices: Module XV – Safety communication
Module XV contains guidance to marketing authorization holders, competent 
authorities in member states and the EMA on how to communicate and 
coordinate safety information in the EU. Communication of safety information 
to patients and healthcare professionals is considered as an important public 
health responsibility. Communication is a broad term but it is necessary to 
achieve the desired level of pharmacovigilance and to promote orthological, 
safe and effective use of medicines, and to prevent risks from adverse 
reactions and as a consequence contribute to the protection of patients’ and 
public health. Communicating the right messages can be quite different from 
‘simple’ dissemination of information
Guideline on good pharmacovigilance 
practices: Module XVI – Risk minimization 
measures: selection of tools and 
effectiveness indicators
Risk minimization measures and pharmacovigilance activities focused on 
the prevention or reduction of the occurrence of adverse reactions that are 
related to the use of a medicinal product, or to reduction of their severity 
or impact on the patient in the case that adverse reactions occur. There is 
a need for risk minimization measures to be planned and implemented. 
After implementation assessment of their effectiveness must occur. 
The combination of all the above-mentioned are key components of risk 
management
Module XVI provides guidance that should be seen in the wider context of 
GVP guidance and in particular in association with Module V
Risk minimization measures usually contain routine risk minimization. 
Additional risk minimization measures can be part of the attempt to 
manage he risk
 
 
 This Module describes the principles in order for MAHs to:
 develop and implement additional risk minimization measures, including 
examples of risk minimization tools
 evaluate the effectiveness of the implemented risk minimization measures 
and their impact
EMA, European Medicines Agency; EU, European Union; MAH, marketing authorization holder; NCA, national competent authority; PSUR, periodic 
safety update report.
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obvious that the above efforts result in greater 
work-sharing leading to a single assessment pro-
cedure with a direct reduction in administrative 
burden. Furthermore, the delivery of a central 
repository of PSURs will also drive the required 
regulatory memory to improve consistent deci-
sion making across PSUR assessments.
In certain cases after the finalization of the PSUR 
procedure, a need for further action like the updat-
ing of the approved summary of product charac-
teristics may be warranted. Importantly, the 
outcomes of the assessment are legally binding 
and on 29 occasions between January 2014 and 
December 2014, PRAC recommended the update 
of the product information (www.ema.europa.eu/
ema/index.jsp?curl=pages/regulation/document_
listing/document_listing_000375.jsp&mid= 
WC0b01ac0580727d1c). Another possible out-
come of PSUR assessment is revocation of the 
MA; however, this would be expected to occur 
only rarely and has not happened in practice [The 
European Parliament and the Council of the 
European, 2010a]. This latter point is crucial for 
MAHs to take note of, as the Directive does not 
provide any legal mechanism for a reexamination 
procedure and the opportunity to reverse a recall 
of the revocation. Thus MAHs should provide 
solid robust arguments from the beginning of the 
procedure. The EU PSUR single assessment is 
commonly referred to as a PSUSA. As a measure to 
increase risk proportionality and improve efficiency 
in resources both for MAHs and for NCAs, there is 
no (routine) requirement for generics, homeopathics, 
and traditional herbal medicines to submit PSURs. A 
list of which active substances are not exempt (i.e. 
that have to submit PSURs) is available on the EU 
reference dates list (EURD list: www.ema.europa.eu/
docs/en_GB/document_library/Other/2012/10/
WC500133159.xls). As of November 2014, the 
EURD list details 3249 active substances (or combi-
nations) with their respective data lock points, as well 
as identifying 228 active substances requiring the 
submission of PSURs for generic and well estab-
lished use medicinal products. Further efficiency 
gains for MAHs are also felt as a result of the deletion 
of the requirement that no more (routine) line listings 
need to be submitted to the regulator. For national 
authorized medicinal products marketed only in a 
single EU member state and whose active substance 
or combination of active substances is included in the 
EURD list, the MAH should submit a PSUR as part 
of the PSUSA procedure. The PSUSA involving only 
NAPs started in the last quarter of 2014 (with data 
lock points after 1 September 2014). For those 
national products with active substances or combi-
nation of active substances not included in the 
EURD list, for which a PSUSA procedure has not 
been established yet, the assessment of PSUR will 
remain at the national level.
The new pharmacovigilance legislation views 
member states as a network of assessors and 
resources with the ultimate objective of safeguard-
ing public health.
Transparency and communication
Major developments have occurred over the last 
2 years in the area of communication and trans-
parency. The EMA has launched a website giv-
ing public access to EudraVigilance and the 
ADR reports contained within it, and in 2014 
this was expanded to cover substances com-
monly found in nationally authorized products. 
The website details alphabetically by product 
and substance the ADR reports submitted to 
EudraVigilance. Furthermore, national web por-
tals on safety issues have been set up by national 
agencies and are linked to the new EU website 
(http://www.adrreports.eu/en/national.html). 
Furthermore, NCAs (examples include the UK’s 
Medicines and Healthcare Products Regulatory 
Agency, www.mhra.gov.uk; the Malta Medicines 
Authority, www.medicinesauthority.gov.mt; the 
Italian Medicines Agency, www.aifa.gov.it; the 
Irish Health Products Regulatory Authority, 
www.hpra.ie; Spanish Medicines Agency, www.
aemps.gob.es), through their websites, provide 
not only product information (summary of prod-
uct characteristics and product information) and 
safety communications, but also approved Dear 
Doctor Letters as well as RMMs (for example, 
patient alert cards, details of registries, educa-
tional materials etc.). The NCA websites are 
host to public assessment reports (including the 
imposed conditions of MAs), lists of products 
under additional monitoring and online ADR 
reporting forms. To date, the EU medicines web 
portal is served by the EMA website (www.ema.
europa.eu), and it is important for industry to 
follow this as recommendations, conclusions 
and opinions of the PRAC, CHMP and coordi-
nation group posted on the EMA website are 
now directly applicable to MAHs. Central to all 
these communication measures is the EMA’s 
role in coordinating and timing the content of 
member state safety announcements, including 
for nationally authorized products outside a for-
mal EU procedure. As a final effort to improve 
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transparency, public hearings linked to pharma-
covigilance referrals (to solicit public views and 
experiences) are being introduced at the level of 
the PRAC [Pharmacovigilance Risk Assessment 
Committee, 2014]. It is anticipated that the first 
such hearings will take place in 2015.
A shift from sending a simple letter to accurately 
communicate the risk and the warning is observed. 
Communication towards all directions regulators 
and agencies and the public is a key element for 
the new pharmacovigilance legislation. The con-
cept introduced is an effort to educate and train 
physicians and the public on how to prevent risks. 
The terms prevention, minimization and proactive 
measures are crucial for the achievement of the 
fundamentals of vigilance.
EU database on drug products and active 
substances
The Article 57 database, referred to in Regulation 
1235/2010/EU, is known as the eXtended 
EudraVigilance Medicinal Product Dictionary 
(XEVMPD) [The European Parliament and the 
Council of the European Union, 2010b]. 
Importantly, MAHs are required to submit infor-
mation to the XEVMPD for all the products for 
which they hold a valid MA in the European 
Economic Area (EEA).
The information submitted to XEVMPD must be 
maintained and updated by the MAHs, as per the 
changes normally occurring in the lifecycle of an 
authorized medicinal product. All other changes 
have to be performed no later than 30 calendar 
days from the date when they became effective, as 
of 1 January 2015 (for variations, 30 calendar days 
from the approval date). One of the main require-
ments of XEVMPD is the submission of the sum-
mary of product characteristics (SmPC), or in the 
absence of the SmPC, an equivalent document 
such as the product information leaflet. This is to 
allow validation of submitted product information 
by the EMA. Another requirement is to submit 
information on all substances contained in the 
medicinal products, including substance classifica-
tion (i.e. chemical, specified substance group 1, 
etc.), bibliographical reference (i.e. company spec-
ification, Martindale, etc.) and translations in all 
languages in which the SmPC exists in the EEA.
According to Article 57 a database will be set up 
and it will contain all SmPCs and patient leaflets 
from all medicinal products authorized in the EU, 
including nationally approved ones. A pool of 
information after ‘cleaning’ and verification of the 
data inserted in the database will be created at the 
end in order to be used by all agencies in EU. This 
can be considered as a step towards harmoniza-
tion of the information available of the medicinal 
products used in member states in Europe and 
could further enhance vigilance for European 
citizens, who due to the freedom of travelling can 
be ‘exposed’ to any medicinal product available in 
any member state of the EU. Information given in 
a common format for the same active substance 
in the same pharmaceutical form will prevent 
‘misunderstandings’ in the use of such active sub-
stances, including avoidance of misuse or abuse.
For ease of reference, Table 4 lists the new addi-
tional fields required. It is important to note that 
the updates discussed above are, in part, to bridge 
the future implementation of the International 
Organization for Standardization Identification of 
Medicinal Products standards.
Another element that needs to be updated by 
MAHs is the SME status of the MAH (small, 
micro, medium enterprise, in which case an SME 
number must be obtained from the EMA’s SME 
office and provided in the update, or N/A, for 
MAHs which do not qualify as SME). This is to 
allow the calculation of the pharmacovigilance fees.
Inspections
A quite new element introduced with the pharma-
covigilance legislation was the mandate to agencies 
to perform inspections. In order to determine 
whether MAHs comply with pharmacovigilance 
obligations established within the EU as well as 
outside the EU, and to facilitate compliance, NCAs 
conduct, in cooperation with the EMA, pharma-
covigilance inspections of MAHs or any firms 
assigned to perform MAH pharmacovigilance 
tasks and activities. NCA inspectors carry out 
inspections and they will have the power to inspect 
premises, records, documents, the PSMF of the 
MAH or any third-party subcontractor contracted 
by the MAH to fulfil the obligations described in 
Title IX of Directive 2001/83/EC for pharma-
covigilance in accordance with Articles 111(1) and 
111(1)(d) [The European Parliament and the 
Council of the European, 2001]. Accordingly, 
there is a shift in the area of compliance with an 
increased reliance on pharmacovigilance inspec-
tions (given that the PSMFs replace the current 
detailed description of the pharmacovigilance 
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Table 4. New fields added for authorized medicinal products.
1. Legal basis [for the MA], where specific values have to be used:
  Full application [Article 8(3) of Directive No. 2001/83/EC]
  Generic application [Article 10(1) of Directive No .2001/83/EC]
  Hybrid application [Article 10(3) of Directive No. 2001/83/EC]
  Similar biological application [Article 10(4) of Directive No. 2001/83/EC]
  Well established use application [Article 10a of Directive No. 2001/83/EC]
  Fixed combination application [Article 10b of Directive No. 2001/83/EC]
  Informed consent application [Article 10c of Directive No. 2001/83/EC]
   Traditional use registration application for a herbal medicinal product (Article 16a of Directive No. 
2001/83/EC)
   Simplified registration application for a homeopathic medicinal product (Article 14 of Directive No. 
2001/83/EC)
  Medicinal product authorized according to Article 126a of Directive No. 2001/83/EC
  Application according to Article 58 of Regulation (EC) No. 726/2004
2. Medicinal product type:
  Authorized homeopathic medicinal product
  Authorized herbal medicinal product
  Parallel distributed/imported medicinal product [Article 76(3) and (4) of Directive No. 2001/83/EC]
  Conditional marketing authorization [Article 14(7) of Regulation (EC) No. 726/2004]
   Exceptional circumstances marketing authorization [Article 14(6) of Regulation (EC) No. 726/2004 or 
Article 22 of Directive 2001/83/EC]
  Paediatric use marketing authorization (PUMA) [Article 31 of Regulation (EC) No. 1901/2006]
  Other
3.  Authorized pharmaceutical form [to be chosen from the code list based on the list published by the 
European Directorate for Quality of Medicines and Healthcare (EDQM)]
4.  Administrable pharmaceutical form (to be chosen from the code list based on the list published by 
EDQM)
system, which is no longer a requirement in the 
EU). It is important to note that PSMFs must be 
in place by July 2015 (MAHs should update their 
dossiers supporting a MA through a Bulk Type IA 
Immediate Notification (Type IAIN)).
Pharmacovigilance inspections have become man-
datory. This should not be interpreted as a ‘polic-
ing’ measure, but rather the creation of an 
environment of direct in person communication 
and interaction between MAHs and regulators at 
the site of the MAH and where pharmacovigilance 
data and reports are kept stored. Inspections can 
be performed on agencies, including their PSMF 
systems. The results of such operations can be 
published, further increasing transparency.
Audit
Article 101(2) of the Directive 2001/83/EC states: 
‘Member States shall, perform a regular audit of 
their Pharmacovigilance system and report the 
results to the Commission on 21 September 2013 
at the latest and then every 2 years thereafter’ 
[The European Parliament and the Council of 
the European, 2001]. Similarly, the Regulation 
imposes requirements for pharmacovigilance 
audit on the EMA. The CIR requires that NCAs 
must have an audit system which is risked based 
[European Commission, 2012] where each 
NCA’s audit strategy is based on its own risk 
assessment, taking into account each area that is 
specified in the CIR. In addition, the NCAs 
should look into the possibility of auditing areas 
where nonconformance is not detected by other 
means (for example, key performance indicators 
within standard operating procedures) and then 
understanding the impact such nonconformance 
could have on public health and the achievement 
of targets set by the CIR [European Commission, 
2012]. Audits carried out by NCAs [European 
Commission 2012; HALMED, 2013, Medicines 
Evaluation Board, 2013] and made available in 
the public domain indicate that NCAs are review-
ing areas of activities (see Table 5) and assign a 
risk rating. According to the audits carried out, 
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the risk assessment is then used to determine the 
priority areas for audits as well as their frequency 
[European Commission, 2012; HALMED, 2013; 
Medicines Evaluation Board, 2013]. The activi-
ties in this area indicate that pharmacovigilance 
audits across the EU are more integrated across 
the EU since 2012 and that compliance with 
Directive requirements could be viewed from a 
‘collective (NCAs/EMA)’ perspective.
Risk management system
A risk management system (RMS) is defined as a 
set of pharmacovigilance activities and interven-
tions designed to identify, characterize, prevent 
or minimize risks relating to a medicinal product, 
including the assessment of the effectiveness of 
those activities and interventions. A RMP is a 
detailed description of the RMS for a medicinal 
product; this requirement was first introduced in 
the EU legislation (the Regulation) in 2005. For 
the sake of clarity it is important to note that an 
RMP summarizes the safety profile of a medici-
nal product, notes the identified risks, identifies 
potential risks and lists the further studies that 
will be carried out post authorization. Any extra 
RMMs required to be put in place to manage the 
identified risks of the medicinal product are 
described in detail. The Directive (Article 106) 
and Regulation (EC) 1235/2010 (Article 26) 
specify that a RMP is required for all new appli-
cations while the summary of the RMP is also to 
be made public [The European Parliament and 
the Council of the European, 2010a, 2010b]. 
This requirement translates to the following 
interpretation: for MAs granted after 21 July 
2012, MAHs are required to operate a RMS for 
each medicinal product. Holders of MAs granted 
before this date are not required to operate a 
RMS for those medicinal products unless regula-
tors or the MAH are concerned about risks 
affecting the benefit–risk balance of an author-
ized medicinal product. Should a RMS for a 
medicinal product be set up, the MAH is legally 
obliged to:
(1) monitor the outcome of RMMs which are 
contained in the RMP or which are laid 
down as conditions of the MA;
(2) update the RMS and monitor pharma-
covigilance data to check for new risks, or 
to establish whether risks have changed or 
Table 5. Areas audited and assigned risk level.
Summary of pharmacovigilance 
systems master files (sPSMFs)
Low risk: the sPSMF, replaces the detailed description of 
pharmacovigilance in dossiers for marketing authorizations. 
These documents are evaluated during pre- and postauthorization 
procedures
Pharmacovigilance inspections Low risk: pharmacovigilance inspections are carried out by NCAs 
on a risk-based approach
RMS High risk: member states need to implement decisions of 
marketing authorizations as per EC decisions
ADRs High risk: member states need to implement a system of 
spontaneous reporting as per Directive 2001/83/EC
PSURs Medium risk: the introduction of PSUSA ensures that these 
procedures will be effectively carried out by NCAs
PASSs Medium risk: not all member states will be involved in PASS. 
However, the PRAC has to evaluate protocols; this ensures that 
the data to be generated from PASS will be robust
Signal management and additional 
monitoring
High risk
Safety communication High risk
Training Medium–high risk: all personnel involved in pharmacovigilance 
have to be competent
General quality system (inclusive 
audits and corrective actions)
High risk: without a GQS both NCAs and industry cannot effectively 
carry out the mandated obligations of the EU legislation
ADR, adverse drug reaction; EU, European Union; GQS, General Quality System; NCA, national competent authority; 
PASS, post-authorisation safety study; PRAC, Pharmacovigilance and Risk Assessment Committee; PSUR, periodic 
safety update report; PSUSA PSURs for Nationally Authorised Products (NAPs) subject to a Single Assessment; RMS, 
risk management system.
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whether there are changes to the benefit–
risk balance of medicinal products.
RMMs are a set of activities which will be done to 
reduce the risk of an event occurring, or to reduce 
the harm from the event associated with a partic-
ular safety concern. The risks identified for a 
product are specified in the RMP. There are two 
types of RMMs:
(1) routine (contraindications and warnings 
contained within the product information);
(2) additional (activities put in place to reduce 
the probability of an event occurring 
through, for example, educational materi-
als for doctors, pharmacists or patients; 
limiting the size of a package; and having a 
pregnancy prevention programme, among 
others. The most commonly reported addi-
tional measures used for risk minimization 
are the educational materials [Zomerdijk 
et al. 2012].
With respect to the RMP summary submitted for 
review by applicants in part VI of the RMP, the 
following elements must be provided.
(1) Overview of disease epidemiology.
(2) Summary of the benefit/efficacy.
(3) Summary of main safety concerns (identi-
fied, potential and missing information).
(4) Summary of RMMs by safety concern 
(routine and additional).
(5) Planned postauthorization (safety and effi-
cacy) development plan.
(6) Major changes over time.
Following the review of the RMP, the summary 
for the public is shared with the company prior 
to publication and published at the time and as 
part of the European Public Assessment Report 
(EPAR) (at time of Commission decision; this 
activity started in 2014 at the level of the EMA 
for CAPs). Importantly, this is linked to the 
product information, European Public 
Assessment Report summary and list of medi-
cines under additional monitoring. It is to be 
kept in mind that the RMP is to be continuously 
updated during the lifecycle of the medicinal 
products and updates should be submitted when 
major changes occur: new indications, restric-
tions of indication, new/updated contraindica-
tions, new important risks or important changes 
to known risks, and any ‘additional risk minimi-
zation measures’ are added or removed. This is 
within the concept of the continuous circle of 
collecting data, reporting and evaluating the 
benefit–risk ratio and confirming whether it 
remains favourable.
ADR reporting and signal detection
The new legislation defines an ADR as ‘a response 
to a medicinal product which is noxious and unin-
tended’. Therefore, other causes of ADRs such as 
MEs, abuse, misuse and occupational exposure 
are also covered by this definition. Thus member 
states and MAHs must report ADRs related to 
MEs to EudraVigilance, which subsequently 
could be upgraded to be able to better handle 
these ME reports. This is because different infor-
mation is required to be captured in an ME report 
to be able to carry out imputability assessment for 
MEs compared with causality assessment for 
adverse events with medicinal products [Tanti 
et al. 2013]. It is interesting to note that the EU 
Directive (2001/83/EC) does not codify that near 
misses of medication errors need to be reported 
[Tanti et  al. 2013]. However, at a national level, 
regulatory agencies could still be interested in 
these reports and could introduce national 
requirements to be able to collect and review near 
misses (www.medicinesauthority.gov.mt/adrpor-
tal). With respect to signal detection, the EU legis-
lation codifies that this activity has to be carried 
out by the EU network, as well as the MAH, with 
NCAs leading for NAPs through work sharing 
and the EMA leading for CAPs. The EMA sup-
ports signal detection through the EudraVigilance 
data warehouse (the EudraVigilance data analysis 
tool) and electronic reaction monitoring reports 
which have been developed specifically to carry 
out signal detection. The EMA defines a safety 
signal as ‘information on a new or incomplete 
documented adverse event that is potentially 
caused by a medicine that warrants further inves-
tigation’ [European Medicines Agency, 2013]. In 
2013, 2449 potential signals were evaluated, which 
equates to approximately an 11% increase versus 
2012 (2213) and a 54% increase versus 2011 
(1586). The signals in 2012 arise from 
EudraVigilance (91%), the literature (5%), and 
other rapid alerts (3%). The rapid alert procedure 
is the procedure used to rapidly communicate 
among competent authorities of member states 
the recall of medicinal products if a serious risk to 
public health has risen with the detection of a 
defect in a product. The aim of the rapid alert pro-
cedure is to transmit only those alerts whose 
urgency and seriousness for potential harm to 
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patients cannot permit any delay in transmission 
and to notify all member states of the issue.
Forty-three validated signals by the EMA were 
further assessed by the PRAC while 69 further 
potential signals were kept under monitoring at 
the EMA [European Medicines Agency, 2013].
It should be noted that the increase in signals can 
be attributed to a great extent to the increased 
pool of information and the expansion of the 
EudraVigilance database via the collection of 
ADRs in the single portal of EudraVigilance and 
the development of tools for the analysis of these 
signals.
Conclusion
In this manuscript we have tried to identify the 
milestones of the EU regulatory network in ful-
filling the legal obligations mandated by EU 
Directives and Regulations. We have attempted 
to carry out this task by discussing the EU phar-
macovigilance network system from a 360° per-
spective, thus describing the current state of 
affairs on all the progress made horizontally by 
EU regulators. The results and data presented 
show that there has been an intensive effort by 
regulators and the industry in setting up systems 
and processes in order to implement the required 
legislative changes. It is evident that public health 
decision making has become much more stream-
lined and transparent with PRAC, which ulti-
mately is being translated into benefits to patients 
through numerous mechanisms; noteworthy are 
harmonized safety labelling changes, regulatory 
action and educational materials for prescribers 
and when necessary for patients. However, there 
are comments in the public domain that indicate 
that the administrative burden with the new sys-
tem has not decreased compared with pre 2012 
[Daniels, 2013; Schofield 2014] and it is noted 
that during 2015 and 2016 new services and sys-
tems will come online to reduce the burden on 
the industry (for example, the EMA literature 
monitoring service). In conclusion, the experi-
ence gained so far with changing trends of dis-
cussion topics every month at the PRAC indicate 
that it is still too early to arrive at an informed 
decision as to whether the legislative tools pro-
vided by the Directive are being utilized in a 
maximal manner. However, from the data pre-
sented, we observe that within the EU, a major 
improvement in implementing safety decisions 
through a rationalized and harmonized approach 
is occurring. This must surely be viewed as a 
major public health contribution of the new EU 
legislative framework.
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